Nasdaq

Tonix Pharmaceuticals To Begin Phase 2 Study Of TNX-2900 For Prader-Willi Syndrome In 2026

(RTTNews) - Tonix Pharmaceuticals Holding Corp. (TNXP) on Monday said it plans to start a Phase 2 study of TNX-2900 for the treatment of Prader-Willi syndrome, a genetic disorder that affects multiple ...
Business Insider

Tonix Pharmaceuticals Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900 (Intranasal Potentiated Oxytocin) in 2026

Phase 2 randomized, double-blind, placebo-controlled trial planned to evaluate TNX-2900 in children and adolescents (ages 8 to 17.5 years) with Prader-Willi Syndrome under a cleared IND TNX-2900 ...
Business Wire

Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin ...
Benzinga.com

Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) released topline results on Wednesday from its Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin (ACP-101) in patients ...
Monthly Prescribing Reference

Intranasal Carbetocin Misses Endpoints in Prader-Willi Syndrome Trial

Treatment with intranasal carbetocin was not associated with a statistically significant improvement in hyperphagia compared with placebo. Topline results were announced from a phase 3 trial ...
STAT

Acadia Pharmaceuticals drug for rare genetic condition fails late-stage study

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
BioWorld

Study identifies ASO targeting UBE3A-ATS for Angelman syndrome

Angelman syndrome (AS) is a rare neurodevelopmental disorder caused by the loss of function of the maternally inherited ubiquitin E3 ligase UBE3A gene. AS is characterized by severe symptoms, ...
Insider Monkey

ACADIA Pharmaceuticals Inc. (ACAD) Nears Key Phase 3 Readout in Prader-Willi Syndrome

In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. ACADIA Pharmaceuticals Inc. stands second among them. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a ...
Business Wire

Ionis receives U.S. FDA Breakthrough Therapy designation for ION582 in Angelman syndrome

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ION582 ...
Insider Monkey

ACADIA Pharmaceuticals Inc. (ACAD) Nears Phase 3 Readout in Prader-Willi Syndrome Trial

We recently compiled a list of the 11 Cheap Biotech Stocks to Buy According to Hedge Funds. Genmab A/S is one of them. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a biopharmaceutical company ...
STAT

Soleno Therapeutics responds to short seller’s Prader-Willi drug safety claims

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...